Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

Lantm��nnen AS-Faktor AB, a subsidiary of Lantm��nnen ek f��r, is a Swedish company located in Stockholm that provides scientific and technical research and development services.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Applera Corp. manufactures medical instruments

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Genset Corp., a subsidiary of Merck KGaA, is a company headquartered in San Diego, CA. The firm manufactures and markets pharmaceuticals. It was founded in 1992.

Serono Genetics Institute SA, a subsidiary of Merck KGaA, is a French company located in Paris. The firm operates a biotechnology company specializing in synthetic DNA and genetic analysis. It was founded in 1989 by Pascal Brandys. Serono Genetics Institute SA was acquired by Serono SA on September 23, 2002 for $65.82 million.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Functions as an investment holding company

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Shanghai Qingliu Biomedical Technology Co., Ltd., established on 2014-06-05, Business scope includes biomedical technology(human stem cells,Except for the development and application of genetic diagnosis and treatment technology)technology development in the field,own technology transfer,And provide relevant technical services and technical advice,Business Consulting(no brokerage). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.